TY - JOUR
T1 - Complete response obtained with first-line therapy as S-1, followed by second-line 5′-DFUR plus paclitaxel therapy in a patient with multiple liver and lymphnode metastases from gastric cancer
AU - Kitajima, Yoshihiko
AU - Yakabe, Tomomi
AU - Ohtsuka, Takao
AU - Tanaka, Masayuki
AU - Sato, Seiji
AU - Nakafusa, Yuji
AU - Miyazaki, Kohji
PY - 2009/5
Y1 - 2009/5
N2 - A 82-year-old man with advanced gastric cancer underwent distal gastrectomy in January 2006. The histological diagnosis was poorly-differentiated adenocarcinoma, T2 (MP), pN2, sH0, sP0, CY0; fStage IIIA. Three months after the operation, two metastatic nodules were noticed on the liver. The patient was treated with S-1 in April 2006. After the 8 courses of S-1 treatment, a complete response was achieved. However, a lymphnode metastasis was newly found adjacent to the remnant stomach 2 months after the complete response to S-1. 5′ -DFUR+paclitaxel combination therapy was then performed. After the 2 courses, the metastatic lymphnode completely disappeared. We continued a total of 18 courses of the 5′ -DFUR+paclitaxel therapy approximately for 1 year without critical drug toxicity. The patient has been alive without any recurrent site. Thus 5′ -DFUR+paclitaxel as a second-line therapy following S-1 should be recommended for a gastric cancer patient with a recurrent tumor.
AB - A 82-year-old man with advanced gastric cancer underwent distal gastrectomy in January 2006. The histological diagnosis was poorly-differentiated adenocarcinoma, T2 (MP), pN2, sH0, sP0, CY0; fStage IIIA. Three months after the operation, two metastatic nodules were noticed on the liver. The patient was treated with S-1 in April 2006. After the 8 courses of S-1 treatment, a complete response was achieved. However, a lymphnode metastasis was newly found adjacent to the remnant stomach 2 months after the complete response to S-1. 5′ -DFUR+paclitaxel combination therapy was then performed. After the 2 courses, the metastatic lymphnode completely disappeared. We continued a total of 18 courses of the 5′ -DFUR+paclitaxel therapy approximately for 1 year without critical drug toxicity. The patient has been alive without any recurrent site. Thus 5′ -DFUR+paclitaxel as a second-line therapy following S-1 should be recommended for a gastric cancer patient with a recurrent tumor.
UR - http://www.scopus.com/inward/record.url?scp=79959840666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959840666&partnerID=8YFLogxK
M3 - Article
C2 - 19461193
AN - SCOPUS:79959840666
SN - 0385-0684
VL - 36
SP - 851
EP - 854
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 5
ER -